Increases color intensity of skin or helps in eliminating the outer layer of epidermis w/ UV radiation (solar or artificial), or in combination w/ photosensitizing agent for psoriasis & idiopathic vitiligo.
Idiopathic vitiligoAdult & childn >12 yr 20 mg/day 2-4 hr before exposure to UVA or sunlight. Therapy should be on alternate days & never on 2 consecutive days. Max dose: 0.6 mg/kg. PsoriasisAdult weighing >115 kg 70 mg, 91-115 kg 60 mg, 81-90 kg 50 mg, 66-80 kg 40 mg, 51-65 kg 30 mg, 30-50 kg 20 mg, <30 kg 10 mg. Doses should be administered 1.5-2 hr before exposure to UVA light, administered 2-3 times wkly (at least 48 hr apart).
Monitor stipulated gradual increase in duration of exposure to UV radiation. Avoid excessive exposure to sunlight after each treatment session. Use sunblock to avoid all risk of burning. Protect the eyes during treatment sessions & for 8-10 hr following treatment. Closely monitor for the potential long-term risk of photochemotherapy eg, skin ageing, changes in pigmentation, basal cell epithelioma & cataract risk. Women of childbearing age should use an effective form of contraception. Pregnancy & lactation.
D05AD02 - methoxsalen ; Belongs to the class of topical psoralens used in the treatment of psoriasis. D05BA02 - methoxsalen ; Belongs to the class of systemic psoralens used in the treatment of psoriasis.
Sign Out
